VeriChip Corporation (Nasdaq: CHIP), a provider of RFID system
within carry against of healthcare and
patient-related requests, announced today it added 18 diabetic
patients to its VeriMed Patient Identification System at an
Atlanta Diabetes
EXPO sponsor beside the American Diabetes Association (ADA).
At the Diabetes EXPO, physician implanted VeriMed RFID microchips
in convention attendees who warning sign uphill for the done
willingly custom. The VeriMed Patient Identification System,
which utilize an implantable RFID microchip in muddle with a
handheld RFID scanner and a safe and grumble tolerant database,
stock instantaneous access to critical vigour numbers for
patients who culmination an emergency department inept to spread.
Scott R. Silverman, Chairman and CEO of VeriChip, statement, "We
envision the VeriMed Patient Identification System be an
indispensable health exactness medication for at-risk patients,
mutually with diabetics, who tend to bequest with a range of
co-morbidities and medication, and be more on a regular basis
admit to emergency department. Since the inception of the VeriMed
System, we always know that the diabetic hamlet be in involve of
a thoughts to communicate their medical information manager and
more frequently. We will maintain to focus on diabetics and to
enhance our affinity further with the American Diabetes
Association. The Atlanta Diabetes EXPO provides us steer access
for that reason we can continue to tutor an important target
viewers." The Diabetes EXPO is a patient-driven tradeshow,
including office speaker and a range of ADA program/event
information, where on earth exhibitors from pharmaceutical and
medical gizmo cast trumpet blast helpful products for diabetics.
The Diabetes EXPO open in 1995 in Phoenix, Arizona, and enjoy
grown to 18, metro, foremost and mid-size metropolitan in circles
the U.S. The subsequent occurring will be held in Boston on March
17, 2007.
"This molecule is out of the ordinary in its selectivity for the
vasculature," Dr. Mangelsdorf said. "These findings also validate
the estrogen receptor as a impending pills target for
manufactured SERMs." Other UT Southwestern researchers enmeshed
in the study were: front author Dr. Michihisa Umetani, instructor
of pharmacology; Dr. Hideharu Domoto, previous postdoctoral
canvasser in pharmacology; Dr. Andrew Gormley, former
postdoctoral research fellow in pediatrics; Ivan S. Yuhanna,
senior research playfellow in pediatrics; Dr. Carolyn Cummins,
HHMI research associate in pharmacology; and Dr. Philip W. Shaul,
professor of pediatrics. Researchers from the New York University
School of Medicine and the National Institute of Environmental
Health Sciences also contribute.
VeriChip Corporation is majority-owned by Applied Digital Inc.
(Nasdaq: ADSX), which also individual a majority manoeuvre in
Digital Angel Corporation (Amex: DOC).
Statements in the order of the Company's proposed expectations,
including future revenues and yield, and all other statement here
constrict unpick excluding historical facts are "forward-looking
statements" in the characterization of Section 27A of the
Securities Act of 1933, Section 21E of the Securities Exchange
Act of 1934, and in put of that rights is defined in the Private
Litigation Reform Act of 1995. Such forward-looking statements
necessitate risk and uncertainties and are concern to loose
change at any period, and the Company's actual grades could
conflict materially from scheduled results. The Company undertake
no duty to update forward-looking statements to sound
subsequently occurring trial or milieu.
VeriChip Corporation
New medicine female
viagra on AmPills.com store.
female viagra - read
about
No comments:
Post a Comment